Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients.

BACKGROUND Sudden death (SD) and acute myocardial infarction (AMI) are the main complications limiting long-term survival after heart transplantation (HT). They are unpredictable and, at present, unpreventable. Platelet aggregation (PA) has recently emerged as a significant prognostic indicator in nontransplanted coronary disease patients. The main purpose of the present study was to evaluate to what extent PA could predict SD and AMI in long-term survivors of HT independently of serum lipid levels. METHODS AND RESULTS We studied 207 patients. All received triple immunosuppressive therapy. During follow-up, the incidence of SD and AMI was determined, and the independent role of PA as predictor was evaluated with other usual risk factors by a Cox multivariate regression model. There were 11 SDs and 14 AMIs after an average follow-up of 642 days, giving an average incidence rate of 7.3 events per year per hundred patients. By univariate analysis, the most potent predictors were ADP-induced platelet aggregation (positive association) and total cholesterol (negative association). Age and length of time since transplant were not predictors. By multivariate analysis, only the secondary wave of ADP-induced platelet aggregation (P = .001) and high-density lipoprotein cholesterol (P = .03) were independent predictors. The relative risk of SD or AMI based on a comparison between patients with high (> 36%) or low (< 36%) ADP-induced platelet aggregation was 4.3 (95% confidence interval, 1.9 to 9.5, P = .0001). CONCLUSIONS This study provides the first demonstration of an association between increased platelet aggregation and subsequent SD or AMI in HT recipients. It suggests that platelets and thrombosis also are implicated in the pathogenesis of AMI and SD in HT recipients. Identification of a safe and effective antiplatelet therapy should be actively pursued.

[1]  M. de Lorgeril,et al.  Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients. , 1993, Transplantation.

[2]  D. Mikhailidis,et al.  Accelerated coronary artery disease after heart transplantation: the role of enhanced platelet aggregation and thrombosis , 1993, Journal of internal medicine.

[3]  J. Arnaud,et al.  Lipid peroxides and antioxidant defenses in accelerated transplantation-associated coronary arteriosclerosis. , 1993, American heart journal.

[4]  B. Hunt,et al.  HEMOSTATIC CHANGES IN HEART TRANSPLANT RECIPIENTS AND THEIR RELATIONSHIP TO ACCELERATED CORONARY SCLEROSIS , 1993, Transplantation.

[5]  S. Kushwaha,et al.  Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients , 1992, The Lancet.

[6]  G. T. Jones Blood platelet count and function are related to total and cardiovascular death in apparently healthy men , 1992 .

[7]  M. de Lorgeril,et al.  Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[8]  J. Emond,et al.  HEPATIC ARTERY THROMBOSIS IN INFANTS A COMPARISON OF WHOLE LIVERS, REDUCED‐SIZE GRAFTS, AND GRAFTS FROM LIVING‐RELATED DONORS 1 , 1992, Transplantation.

[9]  M. de Lorgeril,et al.  Increased lipid peroxidation in cyclosporin-treated heart transplant recipients. , 1991, The American journal of cardiology.

[10]  A. Bluhm Ischemic heart disease and platelet aggregation: The caerphilly collaborative heart disease study , 1991 .

[11]  M. Ovize,et al.  Increased platelet aggregation after heart transplantation: influence of aspirin. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  R. Wilson,et al.  Evidence for Structural Sympathetic Reinnervation After Orthotopic Cardiac Transplantation in Humans , 1991, Circulation.

[13]  S. Alexander,et al.  Graft thrombosis in pediatric renal transplant recipients. A report of the North American Pediatric Renal Transplant Cooperative Study. , 1991, Transplantation.

[14]  S. Hunt,et al.  Progressive coronary luminal narrowing after cardiac transplantation. , 1990, Circulation.

[15]  M. Yacoub,et al.  Coronary artery spasm after cardiac transplantation. , 1990, The American journal of cardiology.

[16]  R. Collins,et al.  Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. , 1989, Circulation.

[17]  J. Schroeder,et al.  The spectrum of coronary artery pathologic findings in human cardiac allografts. , 1989, The Journal of heart transplantation.

[18]  L. Simons,et al.  Platelet activation by oxidatively modified low density lipoproteins. , 1989, Atherosclerosis.

[19]  C Kawai,et al.  Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. , 1988, The Journal of clinical investigation.

[20]  A. Grace,et al.  Cyclosporine A enhances platelet aggregation. , 1987, Kidney international.

[21]  M E Billingham,et al.  Cardiac transplant atherosclerosis. , 1987, Transplantation proceedings.

[22]  T. Lerut,et al.  THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS , 1985, The Lancet.

[23]  A. Buda,et al.  Coronary artery spasm in the denervated transplanted human heart: a clue to underlying mechanisms. , 1981, The American journal of medicine.

[24]  E. Michelson,et al.  Instantaneous and Delayed Ventricular Arrhythmias After Reperfusion of Acutely Ischemic Myocardium: Evidence for Multiple Mechanisms , 1981, Circulation.

[25]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[26]  M. Yacoub,et al.  Detection of Anti-Endothelial Antibodies by Western Blotting - Positive Correlation with Coronary Artery Disease: After Cardiac Transplantation , 1993 .

[27]  J. Hosenpud,et al.  Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  W. S. Ring,et al.  Five-year experience with triple-drug immunosuppressive therapy in cardiac transplantation. , 1990, Circulation.

[29]  N. Arber,et al.  Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.

[30]  H. Cohen,et al.  Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. , 1988, Thrombosis research.

[31]  D.,et al.  Regression Models and Life-Tables , 2022 .